Pharmacologic class (EPC) · 5 drug pages

Calcitonin gene-related peptide receptor antagonist: adverse event reports filed with FDA

18,311 reports list a drug in this class as a suspect or interacting product, 2020–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

18,311
reports across the class: 0.1% of all reports; 2,407
reports, 12 months to June 2026: 2,730 in the 12 months before; 20.9%
marked serious by the reporter: 57.4% across all reports; 5
drugs with a page: brand and generic names counted separately

Calcitonin gene-related peptide receptor antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 5 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 18,311 adverse event reports received by FDA, 0.1% of the database, from January 2020 to June 2026.

2,407 reports arrived in the 12 months to June 2026, down 12% from 2,730 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 20.9% of the class's reports are marked serious, 1.1% record death among the outcomes and 4.5% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (28%), migraine (10.8%) and nausea (9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Nurtec OdtRimegepant sulfate	brand	9,415	712	11.6%	Drug ineffective
QuliptaAtogepant	brand	4,662	748	29.6%	Migraine
UbrelvyUbrogepant	brand	2,833	485	28.8%	Drug ineffective
ZavzpretZavegepant	brand	710	172	7.3%	Dysgeusia
Atogepant	generic	691	290	71.2%	Nausea

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected28%5,134
Migrainemigraine10.8%1,978
Nauseafeeling sick9%1,653
Headachehead pain6.8%1,250
Therapeutic product effect incomplete4.6%850
Off label useused for a purpose or in a way not on the label3.6%656
Dizzinesslight-headedness or unsteadiness3.5%645
Fatiguetiredness3.4%631
Constipationconstipation3.2%580
Vomitingbeing sick2.8%504
Somnolencedrowsiness2.2%407
Feeling abnormalfeeling odd or not right2.2%394
Abdominal pain upperupper stomach pain1.8%322
Painpain, site not specified1.7%303
Rashskin rash1.6%291
Therapeutic product effect decreased1.6%284
Dysgeusiaaltered taste1.4%259
Anxietyanxiety1.4%257
Pruritusitching1.3%246
Malaisegeneral feeling of being unwell1.3%244
Dyspnoeashortness of breath1.2%220
Abdominal discomfortstomach discomfort1.2%216
Hypersensitivityan allergic-type reaction1.2%216
Diarrhoealoose or frequent stools1.2%212
Insomniadifficulty sleeping1.1%208

Solid bar: share of all class reports. Hollow bar: the median share across the 5 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death1.1%203

Life-threatening0.5%90

Hospitalisation (initial or prolonged)4.5%829

Disability1.1%202

Congenital anomaly0.1%27

Other serious16.3%2,986

Not serious79.1%14,480

Patient age

Under 20.3%63

2 to 110%6

12 to 170.5%87

18 to 4414.4%2,639

45 to 6418.9%3,455

65 to 745.5%1,009

75 and over2.3%418

Age not given58.1%10,634

Who reported

Physician9.4%1,723

Pharmacist1.6%285

Other health professional11.1%2,032

Lawyer0%0

Consumer or non-health professional77.8%14,243

Not given0.2%28

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Calcitonin gene-related peptide receptor antagonist reports

Which drugs are in the Calcitonin gene-related peptide receptor antagonist class on this site?

Nurtec Odt, Qulipta, Ubrelvy, Zavzpret and Atogepant. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

18,311 reports through June 2026, 2,407 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (28%), migraine (10.8%), nausea (9%), headache (6.8%) and therapeutic product effect incomplete (4.6%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.